Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 102 citing Bose: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. (0.09 sec) 

Biology of incretins: GLP-1 and GIP

- rh.dk [PDF] 
LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier
This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The published literature was ...
Cited by 179 - Related articles - All 25 versions

Myocardial reperfusion injury

- medicaltherapies.com.au [PDF] 
DM Yellon, DJ Hausenloy - The New England journal of medicine, 2007 - nejm.highwire.org
C oronary heart disease is the leading cause of death world- wide, and 3.8 million men and 3.4
million women die of the disease each year. After an acute myocardial infarction, early and successful
myocardial reperfusion with the use of thrombolytic therapy or primary percutaneous ...
Cited by 178 - Related articles - BL Direct - All 5 versions

The physiology of glucagon-like peptide 1

- physiology.org
JJ Holst - Physiological reviews, 2007 - Am Physiological Soc
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal
epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed
in these cells. The current knowledge regarding regulation of proglucagon gene ...
Cited by 119 - Related articles - BL Direct - All 5 versions

Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1


MC Riddle, DJ Drucker - Diabetes Care, 2006 - Am Diabetes Assoc
Current therapies for type 2 diabetes are frequently associated with inadequate control of postprandial
hyperglycemia, weight gain, and, in the case of oral agents, loss of efficacy over time. A better
understanding of physiological responses to meals is leading to the development of new ...
Cited by 72 - Related articles - BL Direct - All 10 versions

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and …


GG Sokos, LA Nikolaidis, S Mankad, D Elahi, RP … - Journal of cardiac failure, 2006 - Elsevier
We investigated the safety and efficacy of a 5-week infusion of GLP-1 (2.5 pmol/kg/min) added
to standard therapy in 12 patients with New York Heart Association class III/IV heart failure and
compared the results with those of 9 patients with heart failure on standard therapy alone. ...
Cited by 62 - Related articles - All 12 versions

[PDF] Biologic actions and therapeutic potential of the proglucagon-derived peptides


DJ Drucker - Nature Clinical Practice Endocrinology and Metabolism, 2005 - glucagon.com
INTRODUCTION Before the cDNAs and genes encoding pro glucagon were cloned, pancreatic
glucagon was the prin- cipal proglucagon-derived peptide (PGDP) with well-characterized biologic
actions. However, antisera directed against glucagon detected not only circulating ...
Cited by 60 - Related articles - View as HTML - BL Direct - All 6 versions

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of …


JJ Holst, CF Deacon - Current Opinion in Pharmacology, 2004 - Elsevier
Glucagon-like peptide 1 (GLP-1) is a 30 amino acid peptide secreted by intestinal L-cells in response
to meal ingestion. It functions as one of the incretin hormones; that is, the gut hormones that enhance
nutrient-stimulated insulin secretion more than the nutrients themselves, if given ...
Cited by 57 - Related articles - All 2 versions

Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection


DJ Hausenloy, DM Yellon - Heart failure reviews, 2007 - Springer
Abstract Following an acute myocardial infarction (AMI), early coronary artery reperfusion remains
the most effective means of limiting the eventual infarct size. The resultant left ventricular systolic
function is a critical determinant of the patient's clinical outcome. Despite current ...
Cited by 60 - Related articles - BL Direct - All 4 versions

Realizing the clinical potential of ischemic preconditioning and postconditioning.


DM Yellon, DJ Hausenloy - Nature clinical practice. Cardiovascular …, 2005 - ncbi.nlm.nih.gov
After an acute myocardial infarction (AMI), early reperfusion by thrombolysis or primary percutaneous
coronary intervention remains the most-effective strategy for limiting the size of an evolving
infarct. The mortality from AMI, however, remains significant, due partly to the lethal ...
Cited by 52 - Related articles - All 3 versions

Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects


CCT Smith, MM Mocanu, SM Davidson, … - British Journal of …, 2006 - pubmedcentral.nih.gov
Key results: Leptin (10 nM) administered during reperfusion reduced infarct size
significantly. Protection was blocked by either LY294002 or UO126, inhibitors of Akt and
p44/42 MAPK, respectively. Western blotting confirmed that leptin stimulated p44/42 ...
Cited by 42 - Related articles - BL Direct - All 3 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google